Adam Bell
Company: Neuraly
Job title: Vice President - Translational Medicine & Regulatory Affairs
Seminars:
DD01 is a Unique Dual Agonist that Rapidly Reduces Liver Fat, Improves Metabolic Health, & is More Effective than Diet or an Incretin Alone 1:20 pm
DD01 is well tolerated at doses that rapidly reduce hepatic steatosis and improve glucose tolerance in obese diabetics with diabetes and MASLD Mechanistic studies in animals reveal DD01 is more effective than calorie restriction or treatment with a GLP-1 in reducing liver fat and reveal concurrent improvements in clinical markers of MASH resolution that are…Read more
day: Conf Day 1 Track 2 PM
Panel Discussion | Exploring the State of Play with Rezdiffra’s Approval 8:30 am
Discussing the impact of Rezdiffra on the therapeutic treatment of MASH Assessing how clinical trials and other drug classes are affected How will the standard of care be impacted?Read more
day: Conference Day 1 AM